nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—alcohol dependence—nicotine dependence	0.828	1	CtDrD
Citalopram—Meniere's disease—Varenicline—nicotine dependence	0.00557	0.0395	CcSEcCtD
Citalopram—Costochondritis—Varenicline—nicotine dependence	0.00443	0.0314	CcSEcCtD
Citalopram—Change of bowel habit—Varenicline—nicotine dependence	0.00403	0.0285	CcSEcCtD
Citalopram—Terminal insomnia—Varenicline—nicotine dependence	0.0037	0.0262	CcSEcCtD
Citalopram—Snoring—Varenicline—nicotine dependence	0.0032	0.0227	CcSEcCtD
Citalopram—Postnasal drip—Varenicline—nicotine dependence	0.003	0.0213	CcSEcCtD
Citalopram—Middle insomnia—Varenicline—nicotine dependence	0.00283	0.02	CcSEcCtD
Citalopram—Hypogeusia—Varenicline—nicotine dependence	0.00268	0.019	CcSEcCtD
Citalopram—Initial insomnia—Varenicline—nicotine dependence	0.00254	0.018	CcSEcCtD
Citalopram—Upper-airway cough syndrome—Varenicline—nicotine dependence	0.00254	0.018	CcSEcCtD
Citalopram—Chest wall pain—Varenicline—nicotine dependence	0.00254	0.018	CcSEcCtD
Citalopram—Panic reaction—Varenicline—nicotine dependence	0.00231	0.0164	CcSEcCtD
Citalopram—Emotional disorder—Varenicline—nicotine dependence	0.00213	0.0151	CcSEcCtD
Citalopram—Myopia—Varenicline—nicotine dependence	0.00213	0.0151	CcSEcCtD
Citalopram—Gingival pain—Varenicline—nicotine dependence	0.00213	0.0151	CcSEcCtD
Citalopram—Night blindness—Varenicline—nicotine dependence	0.00197	0.014	CcSEcCtD
Citalopram—Restless legs syndrome—Varenicline—nicotine dependence	0.00163	0.0115	CcSEcCtD
Citalopram—Joint stiffness—Varenicline—nicotine dependence	0.00154	0.0109	CcSEcCtD
Citalopram—Sensory disturbance—Varenicline—nicotine dependence	0.0015	0.0106	CcSEcCtD
Citalopram—CYP2B6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00147	0.048	CbGpPWpGaD
Citalopram—Facial paralysis—Varenicline—nicotine dependence	0.00146	0.0103	CcSEcCtD
Citalopram—CYP2E1—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00144	0.0471	CbGpPWpGaD
Citalopram—Anger—Varenicline—nicotine dependence	0.0013	0.00921	CcSEcCtD
Citalopram—Peripheral ischaemia—Varenicline—nicotine dependence	0.00127	0.00902	CcSEcCtD
Citalopram—Varicose vein—Varenicline—nicotine dependence	0.00125	0.00883	CcSEcCtD
Citalopram—Musculoskeletal chest pain—Varenicline—nicotine dependence	0.0012	0.00848	CcSEcCtD
Citalopram—Coronary artery disease—Varenicline—nicotine dependence	0.00118	0.00832	CcSEcCtD
Citalopram—Haematochezia—Varenicline—nicotine dependence	0.00115	0.00817	CcSEcCtD
Citalopram—CYP2B6—Fatty acids—CYP2A7—nicotine dependence	0.00115	0.0375	CbGpPWpGaD
Citalopram—VIIth nerve paralysis—Varenicline—nicotine dependence	0.00113	0.00802	CcSEcCtD
Citalopram—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00111	0.0363	CbGpPWpGaD
Citalopram—Depressed mood—Varenicline—nicotine dependence	0.00104	0.00736	CcSEcCtD
Citalopram—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00102	0.0334	CbGpPWpGaD
Citalopram—Sinus congestion—Varenicline—nicotine dependence	0.000934	0.00661	CcSEcCtD
Citalopram—Throat irritation—Varenicline—nicotine dependence	0.00092	0.00652	CcSEcCtD
Citalopram—Transient ischaemic attack—Varenicline—nicotine dependence	0.00092	0.00652	CcSEcCtD
Citalopram—CYP2B6—Xenobiotics—CYP2A7—nicotine dependence	0.000912	0.0298	CbGpPWpGaD
Citalopram—Suicide—Varenicline—nicotine dependence	0.000895	0.00634	CcSEcCtD
Citalopram—CYP2E1—Xenobiotics—CYP2A7—nicotine dependence	0.000893	0.0292	CbGpPWpGaD
Citalopram—Night sweats—Varenicline—nicotine dependence	0.000861	0.00609	CcSEcCtD
Citalopram—Balance disorder—Varenicline—nicotine dependence	0.00085	0.00602	CcSEcCtD
Citalopram—Urine abnormality—Varenicline—nicotine dependence	0.000839	0.00594	CcSEcCtD
Citalopram—Hostility—Varenicline—nicotine dependence	0.000839	0.00594	CcSEcCtD
Citalopram—Osteoporosis—Varenicline—nicotine dependence	0.000829	0.00587	CcSEcCtD
Citalopram—Sexual dysfunction—Varenicline—nicotine dependence	0.000829	0.00587	CcSEcCtD
Citalopram—Suicide attempt—Varenicline—nicotine dependence	0.000819	0.0058	CcSEcCtD
Citalopram—Gastric ulcer—Varenicline—nicotine dependence	0.000799	0.00566	CcSEcCtD
Citalopram—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.000798	0.0261	CbGpPWpGaD
Citalopram—Completed suicide—Varenicline—nicotine dependence	0.00079	0.00559	CcSEcCtD
Citalopram—Urine analysis abnormal—Varenicline—nicotine dependence	0.00079	0.00559	CcSEcCtD
Citalopram—Platelet count decreased—Varenicline—nicotine dependence	0.000781	0.00553	CcSEcCtD
Citalopram—Toothache—Varenicline—nicotine dependence	0.000764	0.00541	CcSEcCtD
Citalopram—Vaginal discharge—Varenicline—nicotine dependence	0.000764	0.00541	CcSEcCtD
Citalopram—Libido increased—Varenicline—nicotine dependence	0.000764	0.00541	CcSEcCtD
Citalopram—Psoriasis—Varenicline—nicotine dependence	0.000739	0.00523	CcSEcCtD
Citalopram—Electrocardiogram abnormal—Varenicline—nicotine dependence	0.000709	0.00502	CcSEcCtD
Citalopram—Upset stomach—Varenicline—nicotine dependence	0.000709	0.00502	CcSEcCtD
Citalopram—Cyst—Varenicline—nicotine dependence	0.000695	0.00492	CcSEcCtD
Citalopram—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.000689	0.0225	CbGpPWpGaD
Citalopram—Pharyngolaryngeal pain—Varenicline—nicotine dependence	0.000688	0.00487	CcSEcCtD
Citalopram—Menstrual disorder—Varenicline—nicotine dependence	0.000681	0.00483	CcSEcCtD
Citalopram—Paranoia—Varenicline—nicotine dependence	0.000681	0.00483	CcSEcCtD
Citalopram—Laryngeal pain—Varenicline—nicotine dependence	0.000681	0.00483	CcSEcCtD
Citalopram—Haematemesis—Varenicline—nicotine dependence	0.000669	0.00473	CcSEcCtD
Citalopram—Suicidal ideation—Varenicline—nicotine dependence	0.000662	0.00469	CcSEcCtD
Citalopram—Delusion—Varenicline—nicotine dependence	0.000656	0.00465	CcSEcCtD
Citalopram—Thrombosis—Varenicline—nicotine dependence	0.000656	0.00465	CcSEcCtD
Citalopram—Nystagmus—Varenicline—nicotine dependence	0.00065	0.0046	CcSEcCtD
Citalopram—Hyperlipidaemia—Varenicline—nicotine dependence	0.000644	0.00456	CcSEcCtD
Citalopram—Mania—Varenicline—nicotine dependence	0.000639	0.00452	CcSEcCtD
Citalopram—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.000634	0.0207	CbGpPWpGaD
Citalopram—Menorrhagia—Varenicline—nicotine dependence	0.000628	0.00444	CcSEcCtD
Citalopram—Extrapyramidal disorder—Varenicline—nicotine dependence	0.000617	0.00437	CcSEcCtD
Citalopram—Scotoma—Varenicline—nicotine dependence	0.000612	0.00433	CcSEcCtD
Citalopram—Fungal infection—Varenicline—nicotine dependence	0.000602	0.00426	CcSEcCtD
Citalopram—Gingivitis—Varenicline—nicotine dependence	0.000592	0.00419	CcSEcCtD
Citalopram—Mydriasis—Varenicline—nicotine dependence	0.000582	0.00412	CcSEcCtD
Citalopram—Nephrolithiasis—Varenicline—nicotine dependence	0.000578	0.00409	CcSEcCtD
Citalopram—Rhinorrhoea—Varenicline—nicotine dependence	0.000573	0.00406	CcSEcCtD
Citalopram—Dysphonia—Varenicline—nicotine dependence	0.000565	0.004	CcSEcCtD
Citalopram—Endocrine disorder—Varenicline—nicotine dependence	0.00056	0.00397	CcSEcCtD
Citalopram—Acne—Varenicline—nicotine dependence	0.000552	0.00391	CcSEcCtD
Citalopram—Eye irritation—Varenicline—nicotine dependence	0.000544	0.00385	CcSEcCtD
Citalopram—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.000537	0.0175	CbGpPWpGaD
Citalopram—Disturbance in attention—Varenicline—nicotine dependence	0.000536	0.0038	CcSEcCtD
Citalopram—Aggression—Varenicline—nicotine dependence	0.000529	0.00374	CcSEcCtD
Citalopram—Chest discomfort—Varenicline—nicotine dependence	0.000525	0.00372	CcSEcCtD
Citalopram—Accidental injury—Varenicline—nicotine dependence	0.000525	0.00372	CcSEcCtD
Citalopram—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.000514	0.00364	CcSEcCtD
Citalopram—Viral infection—Varenicline—nicotine dependence	0.000514	0.00364	CcSEcCtD
Citalopram—Thinking abnormal—Varenicline—nicotine dependence	0.000507	0.00359	CcSEcCtD
Citalopram—Nocturia—Varenicline—nicotine dependence	0.000501	0.00355	CcSEcCtD
Citalopram—Leukocytosis—Varenicline—nicotine dependence	0.000494	0.0035	CcSEcCtD
Citalopram—Dysarthria—Varenicline—nicotine dependence	0.000491	0.00348	CcSEcCtD
Citalopram—Coordination abnormal—Varenicline—nicotine dependence	0.000473	0.00335	CcSEcCtD
Citalopram—Musculoskeletal pain—Varenicline—nicotine dependence	0.00047	0.00333	CcSEcCtD
Citalopram—Pulmonary embolism—Varenicline—nicotine dependence	0.000465	0.00329	CcSEcCtD
Citalopram—Blood pressure increased—Varenicline—nicotine dependence	0.000465	0.00329	CcSEcCtD
Citalopram—Abnormal dreams—Varenicline—nicotine dependence	0.000459	0.00325	CcSEcCtD
Citalopram—Eructation—Varenicline—nicotine dependence	0.000456	0.00323	CcSEcCtD
Citalopram—Salivary hypersecretion—Varenicline—nicotine dependence	0.000451	0.00319	CcSEcCtD
Citalopram—Influenza like illness—Varenicline—nicotine dependence	0.000451	0.00319	CcSEcCtD
Citalopram—Nightmare—Varenicline—nicotine dependence	0.000449	0.00318	CcSEcCtD
Citalopram—ADRA1A—G alpha (12/13) signalling events—FGD1—nicotine dependence	0.000443	0.0145	CbGpPWpGaD
Citalopram—Photophobia—Varenicline—nicotine dependence	0.000436	0.00309	CcSEcCtD
Citalopram—Dry eye—Varenicline—nicotine dependence	0.000429	0.00304	CcSEcCtD
Citalopram—Oesophagitis—Varenicline—nicotine dependence	0.000424	0.00301	CcSEcCtD
Citalopram—Urine output increased—Varenicline—nicotine dependence	0.00042	0.00297	CcSEcCtD
Citalopram—Mouth ulceration—Varenicline—nicotine dependence	0.00042	0.00297	CcSEcCtD
Citalopram—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.000414	0.0135	CbGpPWpGaD
Citalopram—Hypertonia—Varenicline—nicotine dependence	0.000407	0.00288	CcSEcCtD
Citalopram—Mental disability—Varenicline—nicotine dependence	0.000403	0.00285	CcSEcCtD
Citalopram—Euphoric mood—Varenicline—nicotine dependence	0.000399	0.00283	CcSEcCtD
Citalopram—Lymphadenopathy—Varenicline—nicotine dependence	0.000395	0.0028	CcSEcCtD
Citalopram—HTR2C—Monoamine GPCRs—DRD2—nicotine dependence	0.00039	0.0127	CbGpPWpGaD
Citalopram—Sleep disorder—Varenicline—nicotine dependence	0.00039	0.00276	CcSEcCtD
Citalopram—Diabetes mellitus—Varenicline—nicotine dependence	0.000388	0.00275	CcSEcCtD
Citalopram—Polyuria—Varenicline—nicotine dependence	0.000384	0.00272	CcSEcCtD
Citalopram—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000379	0.0124	CbGpPWpGaD
Citalopram—Deafness—Varenicline—nicotine dependence	0.000377	0.00267	CcSEcCtD
Citalopram—Disorientation—Varenicline—nicotine dependence	0.000377	0.00267	CcSEcCtD
Citalopram—Eczema—Varenicline—nicotine dependence	0.000375	0.00266	CcSEcCtD
Citalopram—CYP2B6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000374	0.0122	CbGpPWpGaD
Citalopram—Eye pain—Varenicline—nicotine dependence	0.000374	0.00264	CcSEcCtD
Citalopram—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000371	0.0121	CbGpPWpGaD
Citalopram—Injury—Varenicline—nicotine dependence	0.000367	0.0026	CcSEcCtD
Citalopram—CYP2E1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000366	0.012	CbGpPWpGaD
Citalopram—Renal failure acute—Varenicline—nicotine dependence	0.000365	0.00259	CcSEcCtD
Citalopram—Libido decreased—Varenicline—nicotine dependence	0.000364	0.00257	CcSEcCtD
Citalopram—Hot flush—Varenicline—nicotine dependence	0.00036	0.00255	CcSEcCtD
Citalopram—Amnesia—Varenicline—nicotine dependence	0.000359	0.00254	CcSEcCtD
Citalopram—Increased appetite—Varenicline—nicotine dependence	0.000359	0.00254	CcSEcCtD
Citalopram—Menopausal symptoms—Varenicline—nicotine dependence	0.000357	0.00253	CcSEcCtD
Citalopram—Atrial fibrillation—Varenicline—nicotine dependence	0.000356	0.00252	CcSEcCtD
Citalopram—Visual disturbance—Varenicline—nicotine dependence	0.000356	0.00252	CcSEcCtD
Citalopram—Thirst—Varenicline—nicotine dependence	0.000354	0.00251	CcSEcCtD
Citalopram—Arthritis—Varenicline—nicotine dependence	0.000347	0.00246	CcSEcCtD
Citalopram—Hypoglycaemia—Varenicline—nicotine dependence	0.000346	0.00245	CcSEcCtD
Citalopram—Cerebrovascular accident—Varenicline—nicotine dependence	0.000344	0.00244	CcSEcCtD
Citalopram—Lethargy—Varenicline—nicotine dependence	0.000344	0.00244	CcSEcCtD
Citalopram—HRH1—Monoamine GPCRs—DRD2—nicotine dependence	0.000338	0.011	CbGpPWpGaD
Citalopram—Osteoarthritis—Varenicline—nicotine dependence	0.000337	0.00239	CcSEcCtD
Citalopram—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.000337	0.00239	CcSEcCtD
Citalopram—CHRM1—Monoamine GPCRs—DRD2—nicotine dependence	0.000337	0.011	CbGpPWpGaD
Citalopram—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.000335	0.00237	CcSEcCtD
Citalopram—Migraine—Varenicline—nicotine dependence	0.000332	0.00235	CcSEcCtD
Citalopram—Affect lability—Varenicline—nicotine dependence	0.000332	0.00235	CcSEcCtD
Citalopram—ADRA1A—Monoamine GPCRs—DRD2—nicotine dependence	0.000332	0.0108	CbGpPWpGaD
Citalopram—Psychotic disorder—Varenicline—nicotine dependence	0.000329	0.00233	CcSEcCtD
Citalopram—SLC6A4—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.000329	0.0108	CbGpPWpGaD
Citalopram—HTR2C—Amine ligand-binding receptors—DRD2—nicotine dependence	0.000328	0.0107	CbGpPWpGaD
Citalopram—Irritability—Varenicline—nicotine dependence	0.000322	0.00228	CcSEcCtD
Citalopram—Urinary retention—Varenicline—nicotine dependence	0.000321	0.00227	CcSEcCtD
Citalopram—Mood swings—Varenicline—nicotine dependence	0.000319	0.00226	CcSEcCtD
Citalopram—SLC6A3—Transmission across Chemical Synapses—CHRNB3—nicotine dependence	0.000313	0.0102	CbGpPWpGaD
Citalopram—Liver function test abnormal—Varenicline—nicotine dependence	0.000311	0.0022	CcSEcCtD
Citalopram—Dry skin—Varenicline—nicotine dependence	0.000309	0.00219	CcSEcCtD
Citalopram—Abdominal pain upper—Varenicline—nicotine dependence	0.000308	0.00218	CcSEcCtD
Citalopram—CYP2B6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000307	0.01	CbGpPWpGaD
Citalopram—Hypokalaemia—Varenicline—nicotine dependence	0.000307	0.00217	CcSEcCtD
Citalopram—Breast disorder—Varenicline—nicotine dependence	0.000305	0.00216	CcSEcCtD
Citalopram—Cramp muscle—Varenicline—nicotine dependence	0.000304	0.00215	CcSEcCtD
Citalopram—Nasopharyngitis—Varenicline—nicotine dependence	0.000302	0.00214	CcSEcCtD
Citalopram—CYP2E1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000301	0.00982	CbGpPWpGaD
Citalopram—Gastritis—Varenicline—nicotine dependence	0.000298	0.00211	CcSEcCtD
Citalopram—SLC6A3—Transmission across Chemical Synapses—CHRNA6—nicotine dependence	0.000297	0.00969	CbGpPWpGaD
Citalopram—Abdominal distension—Varenicline—nicotine dependence	0.000293	0.00208	CcSEcCtD
Citalopram—Asthma—Varenicline—nicotine dependence	0.000291	0.00206	CcSEcCtD
Citalopram—Dysphagia—Varenicline—nicotine dependence	0.000291	0.00206	CcSEcCtD
Citalopram—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000286	0.00934	CbGpPWpGaD
Citalopram—HRH1—Amine ligand-binding receptors—DRD2—nicotine dependence	0.000284	0.00928	CbGpPWpGaD
Citalopram—Angina pectoris—Varenicline—nicotine dependence	0.000284	0.00201	CcSEcCtD
Citalopram—CHRM1—Amine ligand-binding receptors—DRD2—nicotine dependence	0.000283	0.00925	CbGpPWpGaD
Citalopram—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000282	0.00922	CbGpPWpGaD
Citalopram—Bronchitis—Varenicline—nicotine dependence	0.00028	0.00198	CcSEcCtD
Citalopram—Abdominal discomfort—Varenicline—nicotine dependence	0.000279	0.00198	CcSEcCtD
Citalopram—ADRA1A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.000279	0.0091	CbGpPWpGaD
Citalopram—Pollakiuria—Varenicline—nicotine dependence	0.000269	0.00191	CcSEcCtD
Citalopram—Erectile dysfunction—Varenicline—nicotine dependence	0.000268	0.0019	CcSEcCtD
Citalopram—Photosensitivity reaction—Varenicline—nicotine dependence	0.000266	0.00188	CcSEcCtD
Citalopram—Weight increased—Varenicline—nicotine dependence	0.000265	0.00188	CcSEcCtD
Citalopram—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000263	0.00859	CbGpPWpGaD
Citalopram—Hyperglycaemia—Varenicline—nicotine dependence	0.000263	0.00186	CcSEcCtD
Citalopram—Infestation NOS—Varenicline—nicotine dependence	0.00026	0.00184	CcSEcCtD
Citalopram—Infestation—Varenicline—nicotine dependence	0.00026	0.00184	CcSEcCtD
Citalopram—CHRM1—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00026	0.00848	CbGpPWpGaD
Citalopram—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00026	0.00848	CbGpPWpGaD
Citalopram—Depression—Varenicline—nicotine dependence	0.000259	0.00183	CcSEcCtD
Citalopram—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.000258	0.00182	CcSEcCtD
Citalopram—Acute coronary syndrome—Varenicline—nicotine dependence	0.000256	0.00181	CcSEcCtD
Citalopram—Myocardial infarction—Varenicline—nicotine dependence	0.000255	0.0018	CcSEcCtD
Citalopram—Stomatitis—Varenicline—nicotine dependence	0.000253	0.00179	CcSEcCtD
Citalopram—Conjunctivitis—Varenicline—nicotine dependence	0.000253	0.00179	CcSEcCtD
Citalopram—Hepatobiliary disease—Varenicline—nicotine dependence	0.000246	0.00174	CcSEcCtD
Citalopram—Epistaxis—Varenicline—nicotine dependence	0.000245	0.00174	CcSEcCtD
Citalopram—Sinusitis—Varenicline—nicotine dependence	0.000244	0.00173	CcSEcCtD
Citalopram—SLC6A3—Neuronal System—CHRNB3—nicotine dependence	0.00024	0.00783	CbGpPWpGaD
Citalopram—Bradycardia—Varenicline—nicotine dependence	0.000237	0.00168	CcSEcCtD
Citalopram—Hallucination—Varenicline—nicotine dependence	0.000232	0.00164	CcSEcCtD
Citalopram—Hypoaesthesia—Varenicline—nicotine dependence	0.000232	0.00164	CcSEcCtD
Citalopram—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000232	0.00758	CbGpPWpGaD
Citalopram—Urinary tract disorder—Varenicline—nicotine dependence	0.00023	0.00163	CcSEcCtD
Citalopram—Oedema peripheral—Varenicline—nicotine dependence	0.00023	0.00163	CcSEcCtD
Citalopram—Connective tissue disorder—Varenicline—nicotine dependence	0.000229	0.00162	CcSEcCtD
Citalopram—Urethral disorder—Varenicline—nicotine dependence	0.000229	0.00162	CcSEcCtD
Citalopram—SLC6A3—Neuronal System—CHRNA6—nicotine dependence	0.000227	0.00742	CbGpPWpGaD
Citalopram—Visual impairment—Varenicline—nicotine dependence	0.000225	0.00159	CcSEcCtD
Citalopram—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000223	0.00728	CbGpPWpGaD
Citalopram—Erythema multiforme—Varenicline—nicotine dependence	0.000221	0.00156	CcSEcCtD
Citalopram—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00022	0.00719	CbGpPWpGaD
Citalopram—SLC6A4—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00022	0.00717	CbGpPWpGaD
Citalopram—Eye disorder—Varenicline—nicotine dependence	0.000218	0.00154	CcSEcCtD
Citalopram—Tinnitus—Varenicline—nicotine dependence	0.000217	0.00154	CcSEcCtD
Citalopram—Cardiac disorder—Varenicline—nicotine dependence	0.000216	0.00153	CcSEcCtD
Citalopram—SLC6A3—Transmission across Chemical Synapses—GABRA4—nicotine dependence	0.000214	0.007	CbGpPWpGaD
Citalopram—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000213	0.00697	CbGpPWpGaD
Citalopram—Angiopathy—Varenicline—nicotine dependence	0.000212	0.0015	CcSEcCtD
Citalopram—Immune system disorder—Varenicline—nicotine dependence	0.000211	0.00149	CcSEcCtD
Citalopram—Mediastinal disorder—Varenicline—nicotine dependence	0.00021	0.00149	CcSEcCtD
Citalopram—Chills—Varenicline—nicotine dependence	0.000209	0.00148	CcSEcCtD
Citalopram—Arrhythmia—Varenicline—nicotine dependence	0.000208	0.00148	CcSEcCtD
Citalopram—SLC6A3—Transmission across Chemical Synapses—CHRNB4—nicotine dependence	0.000206	0.00671	CbGpPWpGaD
Citalopram—Mental disorder—Varenicline—nicotine dependence	0.000204	0.00145	CcSEcCtD
Citalopram—Erythema—Varenicline—nicotine dependence	0.000203	0.00144	CcSEcCtD
Citalopram—Malnutrition—Varenicline—nicotine dependence	0.000203	0.00144	CcSEcCtD
Citalopram—Flatulence—Varenicline—nicotine dependence	0.0002	0.00142	CcSEcCtD
Citalopram—SLC6A4—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.000199	0.00651	CbGpPWpGaD
Citalopram—Dysgeusia—Varenicline—nicotine dependence	0.000199	0.00141	CcSEcCtD
Citalopram—Back pain—Varenicline—nicotine dependence	0.000196	0.00139	CcSEcCtD
Citalopram—Muscle spasms—Varenicline—nicotine dependence	0.000195	0.00138	CcSEcCtD
Citalopram—Vision blurred—Varenicline—nicotine dependence	0.000191	0.00136	CcSEcCtD
Citalopram—SLC6A3—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.000191	0.00624	CbGpPWpGaD
Citalopram—Tremor—Varenicline—nicotine dependence	0.00019	0.00135	CcSEcCtD
Citalopram—Ill-defined disorder—Varenicline—nicotine dependence	0.000188	0.00133	CcSEcCtD
Citalopram—Anaemia—Varenicline—nicotine dependence	0.000188	0.00133	CcSEcCtD
Citalopram—Agitation—Varenicline—nicotine dependence	0.000187	0.00132	CcSEcCtD
Citalopram—Angioedema—Varenicline—nicotine dependence	0.000186	0.00131	CcSEcCtD
Citalopram—Malaise—Varenicline—nicotine dependence	0.000183	0.0013	CcSEcCtD
Citalopram—Vertigo—Varenicline—nicotine dependence	0.000182	0.00129	CcSEcCtD
Citalopram—Syncope—Varenicline—nicotine dependence	0.000182	0.00129	CcSEcCtD
Citalopram—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000181	0.0059	CbGpPWpGaD
Citalopram—Palpitations—Varenicline—nicotine dependence	0.000179	0.00127	CcSEcCtD
Citalopram—SLC6A4—Circadian rythm related genes—CHRNB2—nicotine dependence	0.000179	0.00586	CbGpPWpGaD
Citalopram—Loss of consciousness—Varenicline—nicotine dependence	0.000178	0.00126	CcSEcCtD
Citalopram—Cough—Varenicline—nicotine dependence	0.000177	0.00125	CcSEcCtD
Citalopram—Convulsion—Varenicline—nicotine dependence	0.000176	0.00125	CcSEcCtD
Citalopram—Hypertension—Varenicline—nicotine dependence	0.000175	0.00124	CcSEcCtD
Citalopram—CYP2B6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000173	0.00565	CbGpPWpGaD
Citalopram—Myalgia—Varenicline—nicotine dependence	0.000173	0.00122	CcSEcCtD
Citalopram—Chest pain—Varenicline—nicotine dependence	0.000173	0.00122	CcSEcCtD
Citalopram—Arthralgia—Varenicline—nicotine dependence	0.000173	0.00122	CcSEcCtD
Citalopram—Anxiety—Varenicline—nicotine dependence	0.000172	0.00122	CcSEcCtD
Citalopram—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000172	0.00562	CbGpPWpGaD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.000172	0.00122	CcSEcCtD
Citalopram—Discomfort—Varenicline—nicotine dependence	0.000171	0.00121	CcSEcCtD
Citalopram—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00017	0.00555	CbGpPWpGaD
Citalopram—CYP2E1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000169	0.00553	CbGpPWpGaD
Citalopram—Dry mouth—Varenicline—nicotine dependence	0.000169	0.0012	CcSEcCtD
Citalopram—Oedema—Varenicline—nicotine dependence	0.000166	0.00117	CcSEcCtD
Citalopram—Infection—Varenicline—nicotine dependence	0.000165	0.00117	CcSEcCtD
Citalopram—SLC6A3—Neuronal System—GABRA4—nicotine dependence	0.000164	0.00537	CbGpPWpGaD
Citalopram—Shock—Varenicline—nicotine dependence	0.000163	0.00115	CcSEcCtD
Citalopram—CYP2B6—Biological oxidations—CYP2A7—nicotine dependence	0.000163	0.00532	CbGpPWpGaD
Citalopram—Nervous system disorder—Varenicline—nicotine dependence	0.000163	0.00115	CcSEcCtD
Citalopram—Thrombocytopenia—Varenicline—nicotine dependence	0.000162	0.00115	CcSEcCtD
Citalopram—Tachycardia—Varenicline—nicotine dependence	0.000162	0.00115	CcSEcCtD
Citalopram—CHRM1—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.000162	0.00528	CbGpPWpGaD
Citalopram—HTR2C—GPCR ligand binding—TAS2R16—nicotine dependence	0.000161	0.00526	CbGpPWpGaD
Citalopram—Skin disorder—Varenicline—nicotine dependence	0.000161	0.00114	CcSEcCtD
Citalopram—CYP2B6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000161	0.00525	CbGpPWpGaD
Citalopram—Hyperhidrosis—Varenicline—nicotine dependence	0.00016	0.00113	CcSEcCtD
Citalopram—CYP2E1—Biological oxidations—CYP2A7—nicotine dependence	0.00016	0.00522	CbGpPWpGaD
Citalopram—Anorexia—Varenicline—nicotine dependence	0.000158	0.00112	CcSEcCtD
Citalopram—SLC6A3—Neuronal System—CHRNB4—nicotine dependence	0.000157	0.00514	CbGpPWpGaD
Citalopram—CYP2E1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000157	0.00514	CbGpPWpGaD
Citalopram—SLC6A3—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.000156	0.00509	CbGpPWpGaD
Citalopram—CHRM1—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.000155	0.00506	CbGpPWpGaD
Citalopram—Hypotension—Varenicline—nicotine dependence	0.000155	0.0011	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.000151	0.00107	CcSEcCtD
Citalopram—Insomnia—Varenicline—nicotine dependence	0.00015	0.00106	CcSEcCtD
Citalopram—Dyspnoea—Varenicline—nicotine dependence	0.000148	0.00105	CcSEcCtD
Citalopram—Somnolence—Varenicline—nicotine dependence	0.000147	0.00104	CcSEcCtD
Citalopram—SLC6A3—Neuronal System—CHRNA5—nicotine dependence	0.000146	0.00478	CbGpPWpGaD
Citalopram—Dyspepsia—Varenicline—nicotine dependence	0.000146	0.00103	CcSEcCtD
Citalopram—Decreased appetite—Varenicline—nicotine dependence	0.000144	0.00102	CcSEcCtD
Citalopram—Gastrointestinal disorder—Varenicline—nicotine dependence	0.000143	0.00101	CcSEcCtD
Citalopram—Fatigue—Varenicline—nicotine dependence	0.000143	0.00101	CcSEcCtD
Citalopram—Pain—Varenicline—nicotine dependence	0.000142	0.001	CcSEcCtD
Citalopram—Constipation—Varenicline—nicotine dependence	0.000142	0.001	CcSEcCtD
Citalopram—HRH1—GPCR ligand binding—TAS2R16—nicotine dependence	0.00014	0.00456	CbGpPWpGaD
Citalopram—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000139	0.00456	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—TAS2R16—nicotine dependence	0.000139	0.00455	CbGpPWpGaD
Citalopram—SLC6A3—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.000137	0.00448	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—TAS2R16—nicotine dependence	0.000137	0.00447	CbGpPWpGaD
Citalopram—Feeling abnormal—Varenicline—nicotine dependence	0.000137	0.000967	CcSEcCtD
Citalopram—Gastrointestinal pain—Varenicline—nicotine dependence	0.000136	0.00096	CcSEcCtD
Citalopram—SLC6A4—Circadian rythm related genes—DRD2—nicotine dependence	0.000133	0.00433	CbGpPWpGaD
Citalopram—Urticaria—Varenicline—nicotine dependence	0.000132	0.000932	CcSEcCtD
Citalopram—Abdominal pain—Varenicline—nicotine dependence	0.000131	0.000928	CcSEcCtD
Citalopram—Body temperature increased—Varenicline—nicotine dependence	0.000131	0.000928	CcSEcCtD
Citalopram—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000131	0.00427	CbGpPWpGaD
Citalopram—SLC6A3—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.000125	0.00407	CbGpPWpGaD
Citalopram—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.000123	0.00402	CbGpPWpGaD
Citalopram—Hypersensitivity—Varenicline—nicotine dependence	0.000122	0.000865	CcSEcCtD
Citalopram—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000122	0.00397	CbGpPWpGaD
Citalopram—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00012	0.00393	CbGpPWpGaD
Citalopram—SLC6A3—Neuronal System—CHRNA3—nicotine dependence	0.000119	0.0039	CbGpPWpGaD
Citalopram—Asthenia—Varenicline—nicotine dependence	0.000119	0.000842	CcSEcCtD
Citalopram—Pruritus—Varenicline—nicotine dependence	0.000117	0.00083	CcSEcCtD
Citalopram—Diarrhoea—Varenicline—nicotine dependence	0.000113	0.000803	CcSEcCtD
Citalopram—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000113	0.0037	CbGpPWpGaD
Citalopram—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000112	0.00365	CbGpPWpGaD
Citalopram—Dizziness—Varenicline—nicotine dependence	0.00011	0.000776	CcSEcCtD
Citalopram—CHRM1—Circadian rythm related genes—CHRNB2—nicotine dependence	0.000107	0.00351	CbGpPWpGaD
Citalopram—Vomiting—Varenicline—nicotine dependence	0.000105	0.000746	CcSEcCtD
Citalopram—SLC6A3—Neuronal System—CHRNB2—nicotine dependence	0.000105	0.00343	CbGpPWpGaD
Citalopram—Rash—Varenicline—nicotine dependence	0.000104	0.00074	CcSEcCtD
Citalopram—Dermatitis—Varenicline—nicotine dependence	0.000104	0.000739	CcSEcCtD
Citalopram—HTR2C—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000104	0.0034	CbGpPWpGaD
Citalopram—Headache—Varenicline—nicotine dependence	0.000104	0.000735	CcSEcCtD
Citalopram—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000102	0.00333	CbGpPWpGaD
Citalopram—SLC6A2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	9.97e-05	0.00326	CbGpPWpGaD
Citalopram—Nausea—Varenicline—nicotine dependence	9.84e-05	0.000697	CcSEcCtD
Citalopram—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	9.6e-05	0.00314	CbGpPWpGaD
Citalopram—SLC6A3—Neuronal System—CHRNA4—nicotine dependence	9.54e-05	0.00312	CbGpPWpGaD
Citalopram—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	9.47e-05	0.00309	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—TAS2R16—nicotine dependence	9.11e-05	0.00297	CbGpPWpGaD
Citalopram—HRH1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	9.02e-05	0.00295	CbGpPWpGaD
Citalopram—CHRM1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	8.99e-05	0.00294	CbGpPWpGaD
Citalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	8.92e-05	0.00291	CbGpPWpGaD
Citalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	8.85e-05	0.00289	CbGpPWpGaD
Citalopram—SLC6A3—Transmembrane transport of small molecules—GABRA4—nicotine dependence	8.83e-05	0.00288	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—TAS2R16—nicotine dependence	8.27e-05	0.0027	CbGpPWpGaD
Citalopram—CHRM1—Circadian rythm related genes—DRD2—nicotine dependence	7.94e-05	0.00259	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—TAS2R16—nicotine dependence	7.89e-05	0.00258	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—TAS2R16—nicotine dependence	7.86e-05	0.00257	CbGpPWpGaD
Citalopram—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	7.86e-05	0.00257	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—TAS2R16—nicotine dependence	7.74e-05	0.00253	CbGpPWpGaD
Citalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	7.73e-05	0.00252	CbGpPWpGaD
Citalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	7.7e-05	0.00252	CbGpPWpGaD
Citalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	7.58e-05	0.00248	CbGpPWpGaD
Citalopram—HTR2C—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	7.53e-05	0.00246	CbGpPWpGaD
Citalopram—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	7.41e-05	0.00242	CbGpPWpGaD
Citalopram—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	7.31e-05	0.00239	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—TAS2R16—nicotine dependence	7.16e-05	0.00234	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—FGD1—nicotine dependence	7.14e-05	0.00233	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—TAS2R16—nicotine dependence	7.14e-05	0.00233	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—TAS2R16—nicotine dependence	7.03e-05	0.0023	CbGpPWpGaD
Citalopram—HTR2C—GPCR ligand binding—OPRM1—nicotine dependence	6.79e-05	0.00222	CbGpPWpGaD
Citalopram—HRH1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	6.52e-05	0.00213	CbGpPWpGaD
Citalopram—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	6.5e-05	0.00212	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—FGD1—nicotine dependence	6.49e-05	0.00212	CbGpPWpGaD
Citalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	6.45e-05	0.00211	CbGpPWpGaD
Citalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	6.4e-05	0.00209	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—FGD1—nicotine dependence	6.19e-05	0.00202	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—FGD1—nicotine dependence	6.17e-05	0.00202	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—FGD1—nicotine dependence	6.08e-05	0.00198	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—OPRM1—nicotine dependence	5.89e-05	0.00192	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—OPRM1—nicotine dependence	5.87e-05	0.00192	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—OPRM1—nicotine dependence	5.78e-05	0.00189	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—FGD1—nicotine dependence	5.62e-05	0.00184	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—FGD1—nicotine dependence	5.6e-05	0.00183	CbGpPWpGaD
Citalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	5.59e-05	0.00183	CbGpPWpGaD
Citalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	5.57e-05	0.00182	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—FGD1—nicotine dependence	5.52e-05	0.0018	CbGpPWpGaD
Citalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	5.48e-05	0.00179	CbGpPWpGaD
Citalopram—HTR2C—GPCR ligand binding—DRD2—nicotine dependence	4.91e-05	0.0016	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TAS2R16—nicotine dependence	4.88e-05	0.0016	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	4.39e-05	0.00143	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—DRD2—nicotine dependence	4.25e-05	0.00139	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—DRD2—nicotine dependence	4.24e-05	0.00139	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TAS2R16—nicotine dependence	4.23e-05	0.00138	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TAS2R16—nicotine dependence	4.22e-05	0.00138	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—DRD2—nicotine dependence	4.18e-05	0.00136	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TAS2R16—nicotine dependence	4.15e-05	0.00136	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—OPRM1—nicotine dependence	3.84e-05	0.00125	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—FGD1—nicotine dependence	3.83e-05	0.00125	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—OPRM1—nicotine dependence	3.49e-05	0.00114	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—AKR1B10—nicotine dependence	3.39e-05	0.00111	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—OPRM1—nicotine dependence	3.33e-05	0.00109	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—FGD1—nicotine dependence	3.32e-05	0.00108	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—OPRM1—nicotine dependence	3.32e-05	0.00108	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—FGD1—nicotine dependence	3.31e-05	0.00108	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—OPRM1—nicotine dependence	3.26e-05	0.00107	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—FGD1—nicotine dependence	3.26e-05	0.00106	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—OPRM1—nicotine dependence	3.02e-05	0.000987	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—OPRM1—nicotine dependence	3.01e-05	0.000983	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—OPRM1—nicotine dependence	2.96e-05	0.000968	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—AKR1B10—nicotine dependence	2.93e-05	0.000958	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—AKR1B10—nicotine dependence	2.92e-05	0.000955	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—AKR1B10—nicotine dependence	2.88e-05	0.00094	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CYP2A7—nicotine dependence	2.79e-05	0.000911	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—DRD2—nicotine dependence	2.78e-05	0.000906	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CYP2A7—nicotine dependence	2.73e-05	0.000892	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—DRD2—nicotine dependence	2.52e-05	0.000823	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—DRD2—nicotine dependence	2.4e-05	0.000785	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—DRD2—nicotine dependence	2.4e-05	0.000783	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—WASF2—nicotine dependence	2.39e-05	0.000779	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—DRD2—nicotine dependence	2.36e-05	0.000771	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—WASF1—nicotine dependence	2.29e-05	0.000747	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—DRD2—nicotine dependence	2.18e-05	0.000713	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—DRD2—nicotine dependence	2.18e-05	0.000711	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—DRD2—nicotine dependence	2.14e-05	0.0007	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CYP2A7—nicotine dependence	2.11e-05	0.000688	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—WASF2—nicotine dependence	2.07e-05	0.000675	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—WASF2—nicotine dependence	2.06e-05	0.000673	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—OPRM1—nicotine dependence	2.06e-05	0.000673	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CYP2A7—nicotine dependence	2.06e-05	0.000672	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—WASF2—nicotine dependence	2.03e-05	0.000662	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—WASF1—nicotine dependence	1.98e-05	0.000647	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—WASF1—nicotine dependence	1.98e-05	0.000645	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—WASF1—nicotine dependence	1.94e-05	0.000635	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CYP2A7—nicotine dependence	1.94e-05	0.000633	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—OPRM1—nicotine dependence	1.78e-05	0.000583	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—OPRM1—nicotine dependence	1.78e-05	0.000581	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—OPRM1—nicotine dependence	1.75e-05	0.000572	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CYP2A7—nicotine dependence	1.64e-05	0.000536	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—DRD2—nicotine dependence	1.49e-05	0.000486	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—DRD2—nicotine dependence	1.29e-05	0.000421	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—DRD2—nicotine dependence	1.29e-05	0.00042	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP2A7—nicotine dependence	1.27e-05	0.000414	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—DRD2—nicotine dependence	1.27e-05	0.000413	CbGpPWpGaD
